2023

Venom Immunotherapy: a 20-year experience with an ultra-rush protocol (210-min)

J. Cosme joanamcosme@gmail.com¹, A. Spínola-Santos¹, M.C. Pereira-Santos^2,3, M Pereira-Barbosa^1,3

Vol. 51 (No. 3) 2019 May

Original Article

doi: 10.23822/EurAnnACI.1764-1489.85

Show more: Authors information and Publication history

Authors Information

¹Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisboa, Portugal
²Laboratório de Imunologia Clínica, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa
³Clínica Universitária de Imunoalergologia, Faculdade de Medicina, Universidade de Lisboa

History

Published online: 31 January 2019
Accepted: 22 January 2019
Received: 5 December 2018

Full text PDF

Table of Content: Vol. 51 (No. 3) 2019 May

Letter to the Editor

When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation

D. Bagnasco diego.bagnasco@dimi.unige.it¹, T. Aloè¹, F. Sclifò², M.G. Ferrantino³, F. Marugo⁴, F. Arcadipane³, A. Manfredi¹, G.W. Canonica⁵, G. Passalacqua¹

doi: 10.23822/EurAnnACI.1764-1489.88

Download PDF

Letter to the Editor

Methylchloroisothiazolinone / methylisothiazolinone: epidemiological retrospective study

A.I. Lorente-Lavirgen ariselae84@gmail.com ¹, C. Almeida², J. Bernabeu¹, V. Valero³, R. Lorente³

doi: 10.23822/EurAnnACI.1764-1489.92

Download PDF

Letter to the Editor

A successful topical treatment for cutaneous inflammatory diseases: an additional or alternative therapy to topical steroids

A. Tammaro tammaroantonella@gmail.com ¹, F. Magri¹, C. Chello¹, D. Giordano¹, F.R. Parisella², G. De Marco¹, S. Persechino¹

doi: 10.23822/EurAnnACI.1764-1489.79

Download PDF

Original Article